About Adverum Biotechnologies, Inc.
https://www.adverum.comAdverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema.
CEO
Laurent Fischer
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-03-21 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 2 of 13
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
SONIC FUND II, L.P.
Shares:6.55M
Value:$28.57M
KAM LAWRENCE
Shares:4.04M
Value:$17.63M
BML CAPITAL MANAGEMENT, LLC
Shares:3.06M
Value:$13.33M
Summary
Showing Top 3 of 82
About Adverum Biotechnologies, Inc.
https://www.adverum.comAdverum Biotechnologies, Inc., a clinical-stage gene therapy company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $46.56M ▼ | $-47.65M ▲ | 0% | $-2.03 ▲ | $-47.19M ▲ |
| Q2-2025 | $0 | $49.85M ▲ | $-49.19M ▼ | 0% | $-2.34 ▼ | $-49.32M ▼ |
| Q1-2025 | $0 | $48.22M ▼ | $-47.02M ▲ | 0% | $-2.25 ▼ | $-47.54M ▲ |
| Q4-2024 | $0 ▼ | $62.22M ▲ | $-60.53M ▼ | 0% ▲ | $-1.96 ▼ | $-61.41M ▼ |
| Q3-2024 | $1M | $30.22M | $-27.13M | -2.71K% | $-1.3 | $-28.33M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $26.06M ▼ | $72.4M ▼ | $128.05M ▲ | $-55.65M ▼ |
| Q2-2025 | $44.4M ▼ | $96.18M ▼ | $116.4M ▲ | $-20.22M ▼ |
| Q1-2025 | $83.08M ▼ | $137.65M ▼ | $111.23M ▲ | $26.42M ▼ |
| Q4-2024 | $125.69M ▼ | $179.84M ▼ | $109.13M ▲ | $70.71M ▼ |
| Q3-2024 | $153.24M | $234.38M | $90.26M | $144.12M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-47.65M ▲ | $-28.11M ▲ | $1.86M ▼ | $9.9M ▲ | $-16.36M ▼ | $-28.26M ▲ |
| Q2-2025 | $-49.19M ▼ | $-38.77M ▲ | $31.9M ▲ | $120K ▲ | $-6.74M ▲ | $-38.89M ▲ |
| Q1-2025 | $-47.02M ▼ | $-42.77M ▼ | $31.28M ▲ | $0 ▼ | $-11.49M ▲ | $-42.99M ▼ |
| Q4-2024 | $-40.93M ▼ | $-28.25M ▼ | $-4.19M ▲ | $239K ▲ | $-32.2M ▲ | $-28.31M ▼ |
| Q3-2024 | $-12.75M | $-21.12M | $-13.35M | $0 | $-34.47M | $-21.34M |
CEO
Laurent Fischer
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-03-21 | Reverse | 1:10 |
ETFs Holding This Stock
Summary
Showing Top 2 of 13
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
SONIC FUND II, L.P.
Shares:6.55M
Value:$28.57M
KAM LAWRENCE
Shares:4.04M
Value:$17.63M
BML CAPITAL MANAGEMENT, LLC
Shares:3.06M
Value:$13.33M
Summary
Showing Top 3 of 82